<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02594241</url>
  </required_header>
  <id_info>
    <org_study_id>2015-806</org_study_id>
    <nct_id>NCT02594241</nct_id>
  </id_info>
  <brief_title>PreOperative Steroid in Abdominal Wall Reconstruction: A Double-blinded Randomized Clinical Trial</brief_title>
  <acronym>POSAR</acronym>
  <official_title>PreOperative Steroid in Abdominal Wall Reconstruction: A Double-blinded Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kristian Kiim Jensen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bispebjerg Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who undergo abdominal wall reconstruction for giant ventral hernia repair will be&#xD;
      randomized to either methylprednisolone or saline preoperatively, to examine the effects of&#xD;
      methylprednisolone on postoperative pain, nausea and recovery after giant ventral hernia&#xD;
      repair.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preoperative high-dose glucocorticoid has been shown to attenuate the postoperative&#xD;
      inflammatory response leading to decreased morbidity and length of stay (LOS) after&#xD;
      colorectal and aortic surgery, as well as decreased pain and subjective recovery after&#xD;
      orthopedic surgery. Methylprednisolone (MP, &quot;Solu-Medrol&quot;) is one such glucocorticoid, which&#xD;
      has been shown to be safe for usage in surgery. Giant ventral hernia repair is associated&#xD;
      with a high risk of postoperative morbidity and prolonged LOS compared with other hernia&#xD;
      repair procedures requiring laparotomy. Further, the total costs of these procedures remain&#xD;
      high. Systemic administration of high-dose preoperative MP in ventral hernia repair has only&#xD;
      been described anecdotally in the literature, and never with the aim to improve the treatment&#xD;
      of this patient group specifically. It is however unknown to what extent benefits weigh out&#xD;
      downsides from usage of high-dose MP in giant ventral hernia repair, patients often at&#xD;
      increased risk of postoperative wound infection. On this background we hypothesize that a&#xD;
      preoperative high-dose MP results in improved recovery after giant ventral hernia repair&#xD;
      compared with placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">November 2018</completion_date>
  <primary_completion_date type="Actual">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain at rest</measure>
    <time_frame>First postoperative day at 8 am</time_frame>
    <description>Self-reported pain at rest on af numerical rating scale (0-10)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain at rest, after moving from supine to sitting position and when coughing</measure>
    <time_frame>8 am and 8 pm pre- and postoperatively until postoperative day 5 and again on day 30</time_frame>
    <description>Self-reported pain at rest, after moving from supine to sitting position and when coughing on af numerical rating scale (0-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>8 am and 8 pm pre- and postoperatively until postoperative day 5 and again on day 30</time_frame>
    <description>Self-reported fatigue on a numerical rating scale (0-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea</measure>
    <time_frame>8 am and 8 pm pre- and postoperatively until postoperative day 5 and again on day 30</time_frame>
    <description>Self-reported nausea on a numerical rating scale (0-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vomiting</measure>
    <time_frame>From randomization until postoperative day 5</time_frame>
    <description>Number of vomiting episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to fulfillment of discharge criteria</measure>
    <time_frame>From randomization until postoperative day 5, assessed at 8 am and 8 pm</time_frame>
    <description>Patient's assessment of discharge criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-postoperative complications</measure>
    <time_frame>From randomization and until 30-days postoperatively</time_frame>
    <description>Complications that require surgical or medical intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day readmission</measure>
    <time_frame>From randomization and until 30-days postoperatively</time_frame>
    <description>Patient readmission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue analgesia intake</measure>
    <time_frame>From randomization and until day 5 postoperatively</time_frame>
    <description>Need for intake of rescue analgesia postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>From day of randomization until postoperative day 3</time_frame>
    <description>Serum C-reactive protein preoperatively and on postoperative day 1-3.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Hernia, Ventral</condition>
  <arm_group>
    <arm_group_label>Methylprednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will be given an intravenous infusion of 125 mg Methylprednisolone (Solu-Medrol) immediately after induction of general anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Physiological saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in this arm will be given an intravenous infusion of saline immediately after induction of general anesthesia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methyl-Prednisolone</intervention_name>
    <description>Single-shot 125 mg infusion given immediately after induction of anesthesia.</description>
    <arm_group_label>Methylprednisolone</arm_group_label>
    <other_name>Solu-Medrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physiological saline</intervention_name>
    <description>A single preoperative dosage 100 ml given intravenously as a 30 minute infusion, 2 hours before surgery</description>
    <arm_group_label>Physiological saline</arm_group_label>
    <other_name>Physiological Saline 9 mg/ml, Fresenius Kabi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ventral incisional hernia with horizontal fascial defect &gt; 10 cm described at either&#xD;
             computed tomography scan or clinical assessment&#xD;
&#xD;
          -  Planned elective open hernia repair&#xD;
&#xD;
          -  Ability to speak and understand Danish&#xD;
&#xD;
          -  Ability to give written and oral informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Daily use of systemic glucocorticoid&#xD;
&#xD;
          -  New York Heart Association class 3-4 heart disease&#xD;
&#xD;
          -  Chronic renal failure (eGFR &lt; 60 ml/min per 1.73 m2)&#xD;
&#xD;
          -  Insulin-dependent diabetes&#xD;
&#xD;
          -  Excessive abuse of alcohol&#xD;
&#xD;
          -  Known allergy to methylprednisolone or any substance in study medicine&#xD;
&#xD;
          -  Planned pregnancy within three months postoperatively&#xD;
&#xD;
          -  Pregnancy, evaluated by pregnancy test preoperatively&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
          -  Actively treated ulcer disease up to one month preoperatively&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristian K Jensen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bispebjerg Hospital, University of Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen NV</city>
        <state>Copenhagen</state>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>October 29, 2015</study_first_submitted>
  <study_first_submitted_qc>October 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2015</study_first_posted>
  <last_update_submitted>September 27, 2020</last_update_submitted>
  <last_update_submitted_qc>September 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Bispebjerg Hospital</investigator_affiliation>
    <investigator_full_name>Kristian Kiim Jensen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Ventral hernia</keyword>
  <keyword>Abdominal wall reconstruction</keyword>
  <keyword>Enhanced recovery after surgery</keyword>
  <keyword>Steroid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hernia</mesh_term>
    <mesh_term>Hernia, Ventral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

